EUVIMEDEUVIMED entdecken
Übersichtsarbeit

From concept to the clinic: Retinoic acid receptor α antagonist YCT‐529, an oral non‐hormonal male contraceptive

Noha Taher iD, Ehfazul Haque iD, Gunda I Georg iD

Andrology · 2026-07 · 14 (5) · 1081-1088

DOI: 10.1111/andr.70106 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Andrology, online erschienen am 12.08.2025. Verfasst von Noha Taher und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicinal Chemistry and Institute for Therapeutics Discovery and Development, University of Minnesota, Minneapolis, Minnesota, USA. Hauptthemen laut MEDLINE: Contraceptive Agents, Male, Receptors, Retinoic Acid. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 48 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

YCT‐529 reversibly reduces sperm counts to infertility levels in mice and non‐human primates. Mice mating studies demonstrated 99% effectiveness in preventing pregnancies. YCT‐529 has completed a first‐in‐class, double‐blind, placebo‐controlled Phase I clinical safety study in men and is currently being investigated in a Phase Ib/IIa clinical study.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Contraceptive Agents, MaleReceptors, Retinoic AcidMaleAnimalsHumansRetinoic Acid Receptor alphaMice

Stichwörter der Autor:innen

antagonismcontraceptionmalenon‐hormonalretinoic acid receptor α

Substanzen

Contraceptive Agents, MaleRetinoic Acid Receptor alphaReceptors, Retinoic Acid

Autor:innen und Institutionen

  • Department of Medicinal Chemistry and Institute for Therapeutics Discovery and Development, University of Minnesota, Minneapolis, Minnesota, USA.

ORCID-Profile: Noha Taher, Ehfazul Haque, Gunda I Georg

Zitieren

APA

Taher, N., Haque, E., & Georg, G. I. (2026). From concept to the clinic: Retinoic acid receptor α antagonist YCT‐529, an oral non‐hormonal male contraceptive. Andrology, 14(5), 1081-1088. https://doi.org/10.1111/andr.70106

Vancouver

Taher N, Haque E, Georg GI. From concept to the clinic: Retinoic acid receptor α antagonist YCT‐529, an oral non‐hormonal male contraceptive. Andrology. 2026;14(5):1081-1088. doi:10.1111/andr.70106

BibTeX
@article{Taher2026,
  author = {Taher, Noha and Haque, Ehfazul and Georg, Gunda I},
  title = {From concept to the clinic: Retinoic acid receptor α antagonist YCT‐529, an oral non‐hormonal male contraceptive},
  journal = {Andrology},
  year = {2026},
  volume = {14},
  number = {5},
  pages = {1081--1088},
  doi = {10.1111/andr.70106}
}
Kostenlos starten →